Oncology

News

AstraZeneca's Imfinzi fails in cervical cancer bid

AstraZeneca's hopes of developing its PD-L1 inhibitor Imfinzi for cervical cancer have been hit by a failed phase 3 trial of the drug alongside chemotherapy as a first-line treatment for wo

News

FDA knocks back MEI's plans for drug in troubled PI3K class

MEI Pharma and partner Kyowa Kirin have had to abandon plans to file for approval of their PI3K inhibitor zandelisib in B cell lymphoma, after being "discouraged" by the FDA from making the

News

Novartis gets first OK for radioligand Pluvicto in prostate ...

Novartis has been steadily investing in radiopharmaceuticals over the last few years, and one of those deals has just paid off with an FDA approval for Pluvicto, the first targeted radiolig

News

Sanofi backs precision oncology firm Nucleai in $33m fundrai...

Israeli startup Nucleai has raised $33 million in a second-round financing that will be used to further its work on using artificial inte

News

Bayer backs KRAS TCR player Affini-T in $175m financing

Bayer's venture capital unit has co-led a $175 million investment in Affini-T that will be used to take its T cell receptor (TCR) therapies for cancer cells with mutations like KRAs and p53

News

Keytruda encroaches on Jemperli's endometrial cancer territo...

Merck & Co's KEYNOTE-158 trial of Keytruda has underpinned another FDA approval, this time for the PD-1 inhibitor as a single-agent therapy as a therapy for endometrial cancer with cert

AstraZeneca's Imfinzi fails in cervical cancer bid

FDA knocks back MEI's plans for drug in troubled PI3K class

Novartis gets first OK for radioligand Pluvicto in prostate ...

Sanofi backs precision oncology firm Nucleai in $33m fundrai...

Bayer backs KRAS TCR player Affini-T in $175m financing

Keytruda encroaches on Jemperli's endometrial cancer territo...

Bankruptcy threat looms as Quince runs out of options

How to meet your physicians where they are online

Oncology

Editor's Picks